Phanes Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10675 Sorrento Valley Rd Ste 100, San Di...Phone Number
(858) 249-7861Website
www.phanesthera.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
1
1
1
1
About Phanes Therapeutics
Phanes Therapeutics, Inc. is a biotech company specializing in innovative drug discovery and early development in the field of immuno-oncology. The company aims to be a significant source of innovation within the biopharma industry by leveraging scientific focus and disruptive technologies. Phanes Therapeutics has developed three technology platforms for creating native IgG-like bispecific antibodies, enhancing drug-like properties, and targeting solid tumors with reduced risk of cytokine release syndrome. Their mission is to illuminate the path to potential cures through revolutionary approaches in drug discovery.Explore more
Phanes Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Phanes Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Phanes Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Phanes Therapeutics
Check out if Phanes Therapeutics is spiking on competitors!
Phanes Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Phanes Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Phanes Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Phanes Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Phanes Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Phanes Therapeutics
Find more new buyers
Compare Similar Companies to Phanes Therapeutics
Compare insights from companies similar to Phanes Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Phanes Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Phanes Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Phanes Therapeutics.
Phanes Therapeutics financials insights
Gather financial insights about Phanes Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$40M
Phanes Therapeutics Tech Stack
A closer look at the technologies used by Phanes Therapeutics
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
New Hire
Executive Move
Phanes Therapeutics News & Media
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
SAN DIEGO, May 28, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, released updated positive Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L)...Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in...Phanes Therapeutics to Present Three Clinical Posters at AACR 2026
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present three posters from their ongoing Phase 2 clinical trial with spevatamig...Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
SAN DIEGO, Jan. 9, 2026 /PRNewswire/ -- Data presented at ASCO GI 2026 show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy, has the potential to be an effective first-line (1L) treatment in patients with CLDN18.2 positive metastatic pancreatic ductal...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Phanes Therapeutics
Sign Up For FreeTo access detailed company insights
Phanes Therapeutics, Inc. is a biotech company specializing in innovative drug discovery and early development in the field of immuno-oncology. The company aims to be a significant source of innovation within the biopharma industry by leveraging scientific focus and disruptive technologies. Phanes Therapeutics has developed three technology platfor... Read More
